Ocular Therapeutix to Unveil New SOL-1 Trial Data at April Conferences
Event summary
- Ocular Therapeutix will present additional SOL-1 Phase 3 trial data for AXPAXLI (OTX-TKI) at three scientific conferences in April 2026.
- Presentations will occur at the 14th Annual Vit-Buckle Society Meeting (April 9-11) and Congreso Nacional de Oftalmologia (April 15-17).
- Key presenters include Ocular's Chief Scientific Officer Jeffrey S. Heier and CEO Pravin U. Dugel.
- AXPAXLI is an investigational treatment for wet age-related macular degeneration (wet AMD) using ELUTYX hydrogel technology.
The big picture
Ocular Therapeutix's upcoming data presentations come at a critical juncture for its lead retinal disease candidate AXPAXLI. The wet AMD market is highly competitive, with established treatments and emerging therapies vying for market share. Successful differentiation through superior clinical data could position AXPAXLI as a key player in this $10B+ market. The company's ELUTYX technology platform represents a strategic asset that, if validated, could support a pipeline of retinal disease treatments.
What we're watching
- Clinical Efficacy
- How the additional SOL-1 data will impact perceptions of AXPAXLI's superiority in treating wet AMD.
- Regulatory Pathway
- Whether positive data presentations will accelerate AXPAXLI's regulatory approval process.
- Market Positioning
- The pace at which Ocular Therapeutix can differentiate AXPAXLI in the competitive wet AMD treatment landscape.